Cancer Cell (journal)

Last updated

History

Cancer Cell was launched in 2002 with the publication of its inaugural issue on February 1, 2002. In an Editorial published in this first issue, Editor-in-Chief Mariana Resnicoff introduced Cancer Cell as "An exciting forum for cancer research". [3] Following in the footsteps of the Cell Press flagship journal Cell, the goal of Cancer Cell was to publish cutting-edge findings in cancer research and to provide great author service by having a team of dedicated scientific editors that hold the highest standards of excellence, editorial consistency, and author service. Li-Kuo Su became Editor-in-Chief in 2003 and is recognized for promoting the journal's growth and establishing it as one of the most reputable cancer research journals. He retired from his editorial activities in 2019. Steve Mao became Cancer Cell's Editor-in-Chief in 2020 after serving as senior editor at Cell and Science.

Changing for a better future editorial

In the April 2020 special issue of Cancer Cell, Steve Mao published the editorial "Changing for a Better Future" [4] delineating his views for the journal. This Editorial reiterated the journal's commitment to scientific excellence and introduced key changes. While Cancer Cell is traditionally considered a journal interested in strong mechanistic studies, the Editorial highlights its interest in translational and clinical studies, as well in discovery papers that scientifically sound and conceptually bold. In line with the Cell Press rebranding strategy launched in 2020, [5] Steve Mao vowed to continue publishing "Science that Inspires". The Editorial also states the editors' commitment to increase communication with its scientific community and authors, as well as to work with authors to improve the revision process of manuscripts under consideration.

Diversity and inclusion efforts

In 2020, Cancer Cell made a number of changes to increase diversity and inclusion of underrepresented minorities in cancer research and oncology. In June 2020, the journal announced the new members of its advisory board (previously editorial board), which includes a higher representation of female scientists (>40%) and physicians (~50%) and higher geographical and ethnic diversity. [6] That same month, the Cell Editorial Team published the editorial "Science has a racism problem", [6] acknowledging the underrepresentation of Black scientists in STEM in the wake of the murders of George Floyd, Breonna Taylor, and Ahmaud Arbery. These events, in conjunction with the anti-immigration policies of the Trump administration in the U.S., led to a Summer of social reckoning in the scientific community. Cancer Cell joined the cancer research and oncology communities and their call for action and change by dedicating its September 2020 issue to the importance of diversity and immigration in cancer research in the U.S. and publishing a series of opinion pieces by scientists and clinicians that represent several minorities (immigrants, Black, Latinx, LGBTQ) and their allies. [7] [8] [9] The journal has also published several articles that address ethnic health disparities and aim to increase the representation of non-Caucasian populations in cancer research and oncology. [10] [11] [12] [13] [14]

As a part of Cell Press, Cancer Cell has supported Black in Cancer and the #BlackInCancerWeek campaign on Twitter. The journal also participated in the creation of the "Rising Black Scientists Award", a cash award granted to one undergraduate student and one graduate student or postdoctoral trainee "meant to break down barriers and create opportunities by providing funds to support professional development". [15]

In January 2021, Cell Press introduced the Inclusion and Diversity Statement, in which authors may choose to disclose information related to how they are increasing their effort to promote genetic diversity in their study subjects, participation of minorities, and balancing gender representation, to name a few. [16]

Related Research Articles

Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.

<i>The Lancet</i> Peer-reviewed general medical journal

The Lancet is a weekly peer-reviewed general medical journal and one of the oldest of its kind. It is also one of the world's highest-impact academic journals. It was founded in England in 1823.

In academic publishing, a retraction is a mechanism by which a published paper in an academic journal is flagged for being seriously flawed to the extent that their results and conclusions can no longer be relied upon. Retracted articles are not removed from the published literature but marked as retracted. In some cases it may be necessary to remove an article from publication, such as when the article is clearly defamatory, violates personal privacy, is the subject of a court order, or might pose a serious health risk to the general public.

AIDS-related lymphoma describes lymphomas occurring in patients with acquired immunodeficiency syndrome (AIDS).

Cancer research is research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure.

<i>Medical Hypotheses</i> Unconventional academic journal (1975-)

Medical Hypotheses is a not-conventionally-peer-reviewed medical journal published by Elsevier. It was originally intended as a forum for unconventional ideas without the traditional filter of scientific peer review, "as long as are coherent and clearly expressed" in order to "foster the diversity and debate upon which the scientific process thrives." The publication of papers on AIDS denialism led to calls to remove it from PubMed, the United States National Library of Medicine online journal database. Following the AIDS papers controversy, Elsevier forced a change in the journal's leadership. In June 2010, Elsevier announced that "submitted manuscripts will be reviewed by the Editor and external reviewers to ensure their scientific merit".

The Cancer Genome Atlas (TCGA) is a project to catalogue the genomic alterations responsible for cancer using genome sequencing and bioinformatics. The overarching goal was to apply high-throughput genome analysis techniques to improve the ability to diagnose, treat, and prevent cancer through a better understanding of the genetic basis of the disease.

<span class="mw-page-title-main">MTA3</span> Protein-coding gene in the species Homo sapiens

Metastasis-associated protein MTA3 is a protein that in humans is encoded by the MTA3 gene. MTA3 protein localizes in the nucleus as well as in other cellular compartments MTA3 is a component of the nucleosome remodeling and deacetylate (NuRD) complex and participates in gene expression. The expression pattern of MTA3 is opposite to that of MTA1 and MTA2 during mammary gland tumorigenesis. However, MTA3 is also overexpressed in a variety of human cancers.

<span class="mw-page-title-main">Ming-Ming Zhou</span>

Ming-Ming Zhou is an American scientist whose specification is structural and chemical biology, NMR spectroscopy, and drug design. He is the Dr. Harold and Golden Lamport Professor and Chairman of the Department of Pharmacological Sciences. He is also the co-director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City, as well as Professor of Sciences. Zhou is an elected fellow of the American Association for the Advancement of Science.

<span class="mw-page-title-main">Tumor microenvironment</span> Surroundings of tumors including nearby cells and blood vessels

The tumor microenvironment is a complex ecosystem surrounding a tumor, composed of cancer cells, stromal tissue and the extracellular matrix. Mutual interaction between cancer cells and the different components of the tumor microenvironment support its growth and invasion in healthy tissues which correlates with tumor resistance to current treatments and poor prognosis. The tumor microenvironment is in constant change because of the tumor's ability to influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing peripheral immune tolerance, while the immune cells in the microenvironment can affect the growth and evolution of cancerous cells.

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. It is a form of xenotransplantation. PDX models are used to create an environment that allows for the continued growth of cancer after its removal from a patient. In this way, tumor growth can be monitored in the laboratory, including in response to potential therapeutic options. Cohorts of PDX models can be used to determine the therapeutic efficiency of a therapy against particular types of cancer, or a PDX model from a specific patient can be tested against a range of therapies in a 'personalized oncology' approach.

Mauro Ferrari is a nanoscientist and leader in the field of nanomedicine. He served as special expert on nanotechnology for the National Cancer Institute (2003-2005) and was instrumental in establishing the Alliance for Nanotechnology in Cancer in 2004. On 1 January 2020, Ferrari was made president of the European Research Council (ERC). Following a vote of no confidence, on 27 March 2020, "all 19 active members of the ERC’s Scientific Council individually and unanimously requested that Mauro Ferrari resign from his position as ERC’s President", due to poor conduct in office, exploiting the position to further his own projects, and for consistently failing to represent the interests of the ERC. On 7 April 2020, Ferrari officially resigned, stating to the media that he was "extremely disappointed by the European response” to the pandemic and expressing frustration over opposition to his efforts to launch a scientific program to combat the virus.

<span class="mw-page-title-main">UK Coronavirus Cancer Monitoring Project</span>

The UK Coronavirus Cancer Programme or UKCCP is one of the longest running UK pandemic research programmes to safeguard, monitor and protect individuals living with cancer from COVID-19 across the United Kingdom.

<span class="mw-page-title-main">Dan Theodorescu</span>

Dan Theodorescu is an American physician and academic. He is the Director of the Samuel Oschin Comprehensive Cancer Institute at the Cedars-Sinai Medical Center and leader of Cedars-Sinai CANCER. From 2010 until 2018, Theodorescu was Director of the University of Colorado Cancer Center and a professor of Surgery-Urology. He has been appointed Paul Mellon Chair at the University of Virginia and Paul Bunn Chair and Distinguished University Professor at the University of Colorado.

<span class="mw-page-title-main">Justin Stebbing</span> British oncology doctor and cancer researcher

Justin Stebbing is a British clinician-scientist specialising in oncology and cancer research. He is a professor of biomedical sciences at Anglia Ruskin University and practices with the private sector Phoenix Hospital Group in London.

Karen E. Knudsen is Chief Executive Officer of American Cancer Society and its advocacy affiliate the American Cancer Society Cancer Action Network. She is the first woman to hold that position in either organization.

<span class="mw-page-title-main">Bisantrene</span> Chemical compound

Bisantrene is an anthracenyl bishydrazone with anthracycline-like antineoplastic activity and an antimetabolite. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in chemotherapeutic activity, but unlike anthracyclines like doxorubicin, it exhibits little cardiotoxicity.

<span class="mw-page-title-main">Alberto Bardelli</span> Italian geneticist

Alberto Bardelli is an Italian geneticist and cancer researcher, expert in the field of precision medicine. He is a full professor of histology at the Department of Oncology, University of Turin and Scientific Director of IFOM, the AIRC Institute of Molecular Oncology.

<span class="mw-page-title-main">Kenneth Tew</span> Scottish-American pharmacologist, academic and author

Kenneth D. Tew is a Scottish-American pharmacologist, academic and author. He is a professor in the Department of Cell & Molecular Pharmacology and the John C. West Endowed Chair in Cancer Research at the Medical University of South Carolina.

Yi Sun is an American scientist of Chinese origin. He is a molecular biologist and oncologist, and his research is focused on how altered protein Ubiquitylation and Neddylation contribute to cancer development. Sun is a Professor Emeritus of Radiation Oncology at the University of Michigan.

References

  1. ↑ "Addendum to the cOAlition S Guidance on the Implementation of Plan S | Plan S". www.coalition-s.org.
  2. ↑ "Elsevier expands Open Access options for Cell Press Journals from January 2021". www.elsevier.com.
  3. ↑ Resnicoff, Mariana (February 2002). "An exciting forum for cancer research". Cancer Cell. 1 (1): 1–2. doi: 10.1016/S1535-6108(02)00019-3 .
  4. ↑ Mao, Steve (April 2020). "Changing for a Better Future". Cancer Cell. 37 (4): 423. doi: 10.1016/j.ccell.2020.03.019 . PMID   32289264.
  5. ↑ The Cell Press Team (29 February 2020). "Science that Inspires". Heliyon. 6 (2): e03362. doi: 10.1016/j.heliyon.2020.e03362 . PMC   7052054 . PMID   32140576.
  6. 1 2 "Editorial Board: Cancer Cell". www.cell.com.
  7. ↑ Merad, Miriam; Posey, Avery D.; Olivero, Ofelia; Singh, Pankaj K.; Mouneimne, Ghassan; Li, Lingyin; Wallace, LaShanale M.; Hayes, Tikvah K. (September 2020). "Diversity Is a Strength of Cancer Research in the U.S." Cancer Cell. 38 (3): 297–300. doi: 10.1016/j.ccell.2020.08.018 . PMC   7489360 . PMID   32931736.
  8. ↑ Morin, Pat J.; Wirtz, Denis; Weeraratna, Ashani T. (September 2020). "Completing the Great Unfinished Symphony of Cancer Together: The Importance of Immigrants in Cancer Research". Cancer Cell. 38 (3): 301–305. doi: 10.1016/j.ccell.2020.08.017 . PMC   7489249 . PMID   32931737.
  9. ↑ Aifantis, Iannis; Neel, Benjamin G. (September 2020). "U.S. Biomedical Research Needs More Immigrant Scientists, Not Fewer!". Cancer Cell. 38 (3): 308. doi: 10.1016/j.ccell.2020.08.010 . PMC   7489325 . PMID   32931738.
  10. ↑ Jiang, Yi-Zhou; Ma, Ding; Suo, Chen; Shi, Jinxiu; Xue, Mengzhu; Hu, Xin; Xiao, Yi; Yu, Ke-Da; Liu, Yi-Rong; Yu, Ying; Zheng, Yuanting; Li, Xiangnan; Zhang, Chenhui; Hu, Pengchen; Zhang, Jing; Hua, Qi; Zhang, Jiyang; Hou, Wanwan; Ren, Luyao; Bao, Ding; Li, Bingying; Yang, Jingcheng; Yao, Ling; Zuo, Wen-Jia; Zhao, Shen; Gong, Yue; Ren, Yi-Xing; Zhao, Ya-Xin; Yang, Yun-Song; Niu, Zhenmin; Cao, Zhi-Gang; Stover, Daniel G.; Verschraegen, Claire; Kaklamani, Virginia; Daemen, Anneleen; Benson, John R.; Takabe, Kazuaki; Bai, Fan; Li, Da-Qiang; Wang, Peng; Shi, Leming; Huang, Wei; Shao, Zhi-Ming (March 2019). "Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies". Cancer Cell. 35 (3): 428–440.e5. doi: 10.1016/j.ccell.2019.02.001 . PMID   30853353.
  11. ↑ Carrot-Zhang, Jian; Chambwe, Nyasha; Damrauer, Jeffrey S.; Knijnenburg, Theo A.; Robertson, A. Gordon; Yau, Christina; Zhou, Wanding; Berger, Ashton C.; Huang, Kuan-lin; Newberg, Justin Y.; Mashl, R. Jay; Romanel, Alessandro; Sayaman, Rosalyn W.; Demichelis, Francesca; Felau, Ina; Frampton, Garrett M.; Han, Seunghun; Hoadley, Katherine A.; Kemal, Anab; Laird, Peter W.; Lazar, Alexander J.; Le, Xiuning; Oak, Ninad; Shen, Hui; Wong, Christopher K.; Zenklusen, Jean C.; Ziv, Elad; Cherniack, Andrew D.; Beroukhim, Rameen; Aguet, Francois; Ding, Li; Demchok, John A.; Mensah, Michael K.A.; Caesar-Johnson, Samantha; Tarnuzzer, Roy; Wang, Zhining; Yang, Liming; Alfoldi, Jessica; Karczewski, Konrad J.; MacArthur, Daniel G.; Meyerson, Matthew; Benz, Christopher; Stuart, Joshua M. (May 2020). "Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer". Cancer Cell. 37 (5): 639–654.e6. doi: 10.1016/j.ccell.2020.04.012 . PMC   7328015 . PMID   32396860.
  12. ↑ Whisenant, Jennifer G.; Trama, Annalisa; Torri, Valter; De Toma, Alessandro; Viscardi, Giuseppe; Cortellini, Alessio; Michielin, Olivier; Barlesi, Fabrice; Dingemans, Anne-Marie C.; Van Meerbeeck, Jan; Pancaldi, Vera; Soo, Ross A.; Leighl, Natasha B.; Peters, Solange; Wakelee, Heather; Garassino, Marina Chiara; Horn, Leora (June 2020). "TERAVOLT: Thoracic Cancers International COVID-19 Collaboration". Cancer Cell. 37 (6): 742–745. doi: 10.1016/j.ccell.2020.05.008 . PMC   7229923 . PMID   32425702.
  13. ↑ Bernabe-Ramirez, Carolina; Velazquez, Ana I.; Olazagasti, Coral; Bergerot, Cristiane Decat; Bergerot, Paulo Gustavo; Soto-Perez-de-Celis, Enrique; Duma, Narjust (November 2020). "The HOLA COVID-19 Study: An International Effort to Determine How COVID-19 Has Impacted Oncology Practices in Latin America". Cancer Cell. 38 (5): 605–608. doi: 10.1016/j.ccell.2020.10.013 . PMC   7553055 . PMID   33098754.
  14. ↑ Schmidt, Andrew L.; Bakouny, Ziad; Bhalla, Sheena; Steinharter, John A.; Tremblay, Douglas A.; Awad, Mark M.; Kessler, Alaina J.; Haddad, Robert I.; Evans, Michelle; Busser, Fiona; Wotman, Michael; Curran, Catherine R.; Zimmerman, Brittney S.; Bouchard, Gabrielle; Jun, Tomi; Nuzzo, Pier V.; Qin, Qian; Hirsch, Laure; Feld, Jonathan; Kelleher, Kaitlin M.; Seidman, Danielle; Huang, Hsin-Hui; Anderson-Keightly, Heather M.; Abou Alaiwi, Sarah; Rosenbloom, Talia D.; Stewart, Penina S.; Galsky, Matthew D.; Choueiri, Toni K.; Doroshow, Deborah B. (December 2020). "Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study". Cancer Cell. 38 (6): 769–770. doi: 10.1016/j.ccell.2020.10.023 . PMC   7609043 . PMID   33176161.
  15. ↑ "Announcing the Rising Black Scientists Awards". www.cell.com.
  16. ↑ Sweet, Deborah J. (January 2021). "New at Cell Press: The Inclusion and Diversity Statement". Cell. 184 (1): 1–2. doi: 10.1016/j.cell.2020.12.019 . PMID   33417857.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.